| A review of clinical characteristics and genetic backgrounds in Alport syndrome |
29 |
| Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018 |
24 |
| Clinical epidemiology of infectious disease among patients with chronic kidney disease |
19 |
| Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy |
14 |
| Independent regulation of renin-angiotensin-aldosterone system in the kidney |
12 |
| Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study) |
12 |
| T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target |
10 |
| Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats |
10 |
| The Japanese clinical practice guideline for acute kidney injury 2016 |
10 |
| Home-based versus center-based aerobic exercise on cardiopulmonary performance, physical function, quality of life and quality of sleep of overweight patients with chronic kidney disease |
9 |
| Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis |
9 |
| Biopsy-based estimation of total nephron number in Japanese living kidney donors |
9 |
| Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease |
9 |
| New strategies and perspectives on managing IgA nephropathy |
8 |
| Pharmacological interventions for the prevention of acute kidney injury after pediatric cardiac surgery: a network meta-analysis |
7 |
| Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome |
7 |
| Melatonin ameliorates intrarenal renin-angiotensin system in a 5/6 nephrectomy rat model |
7 |
| Detection of copy number variations by pair analysis using next-generation sequencing data in inherited kidney diseases |
7 |
| A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes |
7 |
| Clinical and histological features and therapeutic strategies for IgA nephropathy |
7 |
| Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy |
7 |
| Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study |
7 |
| The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5 |
7 |
| The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia |
7 |
| The assessment of renal cortex and parenchymal volume using automated CT volumetry for predicting renal function after donor nephrectomy |
6 |
| Decreased KLHL3 expression is involved in the pathogenesis of pseudohypoaldosteronism type II caused by cullin 3 mutation in vivo |
6 |
| Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial |
6 |
| Recent advances of animal model of focal segmental glomerulosclerosis |
6 |
| AQP2 in human urine is predominantly localized to exosomes with preserved water channel activities |
6 |
| Ionized and total serum magnesium in hemodialysis: predictors and variability. A longitudinal cross-sectional study |
6 |
| Dipstick proteinuria and all-cause mortality among the general population |
6 |
| A retrospective analysis of children with Henoch-Schonlein purpura and re-evaluation of renal pathologies using Oxford classification |
6 |
| Oral adsorbent AST-120 ameliorates gut environment and protects against the progression of renal impairment in CKD rats |
6 |
| Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology |
6 |
| rAAV6-mediated miR-29b delivery suppresses renal fibrosis |
5 |
| Clinico-pathological features of kidney disease in diabetic cases |
5 |
| A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac (TM), as compared to Engerix B-A (R), among vaccine na < ve and vaccine non-responder dialysis patients |
5 |
| Interaction of CD80 with Neph1: a potential mechanism of podocyte injury |
5 |
| Effect of Npt2b deletion on intestinal and renal inorganic phosphate (Pi) handling |
5 |
| Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus |
5 |
| Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis |
5 |
| Long-term renal outcome in pediatric glomerulonephritis associated with crescent formation |
5 |
| Effect of essential amino acid ketoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and ?lotho) in 3b-4 stages chronic kidney disease patients: a randomized pilot study |
5 |
| Novel tubular-glomerular interplay in diabetic kidney disease mediated by sirtuin nicotinamide mononucleotide, and nicotinamide adenine dinucleotide Oshima Award Address 2017 |
5 |
| Urine exosomal ceruloplasmin: a potential early biomarker of underlying kidney disease |
5 |
| Clinical importance of potassium intake and molecular mechanism of potassium regulation |
5 |
| Forced expression of vascular endothelial growth factor-A in podocytes decreases mesangial cell numbers and attenuates endothelial cell differentiation in the mouse glomerulus |
5 |
| Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120 |
5 |
| Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials |
5 |
| Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism |
5 |
